Market insight in association with

Otsuka and Magellan Health collaborate to launch first digital pill

Otsuka recently announced it has entered into a collaboration with Magellan Health to distribute its Abilify MyCite digital pill — a unique antipsychotic that has a Proteus Digital Health sensor embedded in the tablet. The drug-device was initially approved by the FDA in November 2017, facing criticism over the potential consequences of ingestible sensors and its $1,650-a-month price tag.

However, Otsuka hopes the new collaboration will provide a chance to collect additional real-world data before wider release in the US; Magellan is ideally placed to help gather this data, as a US-managed healthcare company with a strong focus on mental health. Ultimately, the goal is to ease concerns with the drug-device, which will lead to more partnerships with payer groups going forward.

The MyCite pill is a first in not only neurology, but all of healthcare: a sensor is placed inside the tablet and linked to a smart patch in order to monitor dosing and adherence to medication, as well as other health metrics, when the tablet has been ingested. This information can then be synced and downloaded to a Bluetooth-enabled device.

A new solution for the schizophrenia market?

According to the GlobalData PharmaPoint: Schizophrenia report, adherence is one of the largest unmet needs in the schizophrenia market, and a physician being able to see exactly when a patient has or has not taken their pills would go a long way to addressing this.

However, the main issues that stakeholders have raised with the digital pill revolve around the use of such technology in patient care, with some raising the point that patients with schizophrenia often have paranoia with thoughts of being tracked or followed, and giving them a tablet with a sensor in it may spark a decline in their mental state.

To combat this, a small initial rollout is expected under the Otsuka-Magellan collaboration, which will aim to collect real-world data on adherence; if the MyCite pill can show a marked improvement, other payers might be convinced to include it in reimbursement lists moving forward.

We are likely to see more digital therapies enter the market, as pharmaceutical companies increasingly look to technology to help address unmet clinical needs in the market. While there will still be opposition to the adoption of technology in healthcare, the Otsuka-Magellan collaboration could act as a template for other pharmaceutical companies looking to launch these novel treatments.

For more insight and data, visit the GlobalData Report Store.

Share this article

Go to article: Home | The race to regulate 3D printed devicesGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: In this issueGo to article: MPS Microsystems Company InsightGo to article: MPS MicrosystemsGo to article: ContentsGo to article: Micro Systems TechnologiesGo to article: Cap Biomaterials Company Insight Go to article: Cap BiomaterialsGo to article: NewsGo to article: MikronGo to article: Ide8Go to article: The medical industry briefingGo to article: Protomatic Company InsightGo to article: Protomatic MedicalGo to article: Automation vs AI in medtech: where are we headed?Go to article: Telemed Company InsightGo to article: TelemedGo to article: NSFGo to article: A breakthrough in 3D-printed neuronal stem cells and scaffold therapyGo to article: ElectroCraftGo to article: ElectroCraft Company InsightGo to article: Maxon MotorGo to article: Otsuka and Magellan Health collaborate to launch first digital pillGo to article: Bright PlasticsGo to article: ARPA Company InsightGo to article: ARPAGo to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Novartis aims to disrupt healthcare with ‘digital ecosystem’Go to article: Linemaster Company InsightGo to article: LinemasterGo to article: Performance Motion Devices Company InightGo to article: Performance Motion DevicesGo to article: Will FDA’s new guidance boost medical device cybersecurity?Go to article: Machine Solutions Company InsightGo to article: Machine SolutionsGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Transporting human organs: the innovations saving livesGo to article: Maraca InternationalGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Breaking point: should we be reusing more medical devices?Go to article: ABBGo to article: ABB Company InsightGo to article: 3D printed medical devices: a tough trial for regulation?Go to article: Ash TechnologiesGo to article: Innomech Company InsightGo to article: InnomechGo to article: Cutting complete blood count tests from days to minutesGo to article: Medica LLC Company InsightGo to article: Medica LLCGo to article: AberdeenGo to article: “At least I have my health”: the reputational impact of AI in healthcareGo to article: Freund ElectronicGo to article: myLiquitabGo to article: Amplifying the patient voice and the role of linguistic validationGo to article: Art of TechnologyGo to article: AerotechGo to article: Erdmann Design SwitzerlandGo to article: Human + machine: the future of digital healthcareGo to article: Velixx Company InsightGo to article: VelixxGo to article: EventsGo to article: Lubrizol LifeSciencesGo to article: CS Hyde CompanyGo to article: Next issue